PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsEmbryonic stem cell pioneers receive offer for abandoned programme from former executives

BioNews

Embryonic stem cell pioneers receive offer for abandoned programme from former executives

Published 19 October 2012 posted in News and appears in BioNews 678

Author

Dr Anna Cauldwell

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.

Two former CEOs of US drug company Geron are bidding to revive its stem cell assets...

Two former CEOs of US drug company Geron are bidding to revive
its stem cell assets. Dr Michael West and Dr Thomas Okarma, who now work for
BioTime, issued an open letter to Geron's shareholders putting forward an offer
for the company's stem cell research programme, which has been suspended since
2011.

Dr West founded Geron in 1990, where he was director and vice-president until 1998 when he moved to Advanced Cell Technology. He was appointed CEO of BioTime, a biotechnology company focusing on
regenerative medicine based in California, USA in 2007. Dr Okarma was CEO of Geron
between 1999 and 2011. However, following Geron's move away from stem cell
research, Dr Okarma joined Biotime in September 2012.

Both men have spent much of their careers trying to bring products
derived from embryonic stem cells to the clinic. The letter to Geron's shareholders states they see this bid as an
opportunity to 'put the now dormant Geron stem cell assets
back on track'.

The proposal outlines an arrangement in which certain stem
cell assets owned by BioTime would be combined with those of Geron and controlled
by a new publicly traded company called BioTime Acquisition (BAC), to be led
by Dr Okarma.

Under the proposal, Geron shareholders would receive a 21.4
percent stake in the new company and subscription rights to purchase further
stock in BAC, with the potential to increase their ownership up to 45 percent.
BioTime would contribute $40 million in BioTime common shares, together with
BioTime warrants valued at $13 million and shares in BioTimes subsidiaries.

Although the final decision rests with Geron's board of
directors, the letter urges shareholders to contact the board in a bid to
encourage them to accept the proposal. The letter reminds shareholders that 'nearly
a year has now passed, and Geron has not announced any transaction that would
provide value to either Geron or its shareholders from those stem cell assets'.

Geron is yet to respond. However, the company's share prices
rose following the announcement, leading to speculation that Geron's investors
are interested in negotiating a deal.

Geron is currently focussed on developing
anti-cancer drugs, but it was previously an important player in stem cell research
and had pioneered development into stem cell based treatment for spinal cord
injury. Dr West and Dr Okarma believe that acceptance of their bid would 'speed
the development and commercialisation of innovative new products to treat
degenerative diseases'.

Related Articles

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
10 January 2013 • 2 minutes read

Embryonic stem cell pioneers shut down trial

by Rosemary Paxman

A US drug company is abandoning its research into a novel paralysis treatment using embryonic stem cells, due to current economic conditions....

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family (from Greek and Roman mythology) entwined in coils of DNA.
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family entwined in coils of DNA (based on the figure of Laocoön from Greek and Roman mythology).
News
7 December 2012 • 1 minute read

$3 billion California stem cell agency 'make proposals to themselves regarding what should be funded'

by Dr Anna Cauldwell

A report has drawn attention to the potential for conflict of interest at the agency that allocates state funds to stem cell research in California, USA...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
12 November 2012 • 3 minutes read

Critically ill patient dies after Pluristem claims stem cell treatment a 'success'

by Dr Daniel Grimes

A biotechnology company has come under fire after reporting success of its 'life-saving' stem cell based therapies ahead of a major stock sale, which occurred before investors became aware of news that a patient who had received its treatment had died....

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
15 February 2012 • 1 minute read

First clinical trial of human embryonic stem cells gets go-ahead

by Marianne Kennedy

Biotechnology company Geron has been given the all clear for the world's first clinical trial involving human embryonic stem cells (hESCs). This comes a year after the US Food and Drug Administration (FDA) placed the study on hold amid safety fears...

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
28 August 2009 • 2 minutes read

Geron issues statement on halted stem cell trial

by Nishat Hyder

Information has come to light regarding the US Food and Drug Adminstration (FDA)'s freeze on the clinical trails of GRNOPC1, a groundbreaking therapy for spinal cord injury derived from human embryonic stem cells (ES cells) being undertaken by biotech company Geron...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
9 June 2009 • 2 minutes read

FDA approves embryonic stem cell therapy for clinical trials

by Dr Antony Starza-Allen

The US Food and Drug Administration (FDA) has allowed the biotech firm, Geron, to begin clinical trials using embryonic stem (ES) cells to help treat spinal cord injury sufferers who have become paralysed from the chest down. The product known as GRNOPC1 will be tested for its...

PET BioNews
News
9 June 2009 • 1 minute read

Geron patents stem cell separation technique

by BioNews

Geron, a US biotechnology company, announced last week that it has patented a process that allows them to 'purify' batches of human embryonic stem (ES) cells. The patented process would allow scientists to separate useful ES cells from potentially harmful cells and would give Geron an advantage over other companies...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Celebrity sperm donor hoax revealed

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

15 August 2022 • 2 minutes read

Call to end ban on HIV-positive partner gamete 'donation'

15 August 2022 • 2 minutes read

Melanoma invades new tissues using nerve cell gene

15 August 2022 • 2 minutes read

Exceeding alcohol limits could damage DNA and accelerate ageing

15 August 2022 • 2 minutes read

Blood cell gene mutations affect mitochondria, increasing cardiovascular disease risk

15 August 2022 • 2 minutes read

Jumping gene helps immune system fight viruses

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856